139 related articles for article (PubMed ID: 30180464)
1. [Oral melphalan plus high-dose dexamethasone as first-line therapy for patients with primary light chain amyloidosis].
Zhang CL; Shen KN; Feng J; Cao XX; Mao YY; Zhang L; Su W; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):641-644. PubMed ID: 30180464
[No Abstract] [Full Text] [Related]
2. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.
Palladini G; Milani P; Foli A; Obici L; Lavatelli F; Nuvolone M; Caccialanza R; Perlini S; Merlini G
Haematologica; 2014 Apr; 99(4):743-50. PubMed ID: 24213149
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients.
Liu B; Wang Y; Bai M; Wang D; Zhao J; Zhang M; Sun S
Clin Ther; 2019 Jun; 41(6):1186-1198. PubMed ID: 30718006
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
[TBL] [Abstract][Full Text] [Related]
8. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
Sanchorawala V; Seldin DC; Berk JL; Sloan JM; Doros G; Skinner M
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):469-72. PubMed ID: 21156464
[TBL] [Abstract][Full Text] [Related]
9. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
11. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.
Dietrich S; Schönland SO; Benner A; Bochtler T; Kristen AV; Beimler J; Hund E; Zorn M; Goldschmidt H; Ho AD; Hegenbart U
Blood; 2010 Jul; 116(4):522-8. PubMed ID: 20375312
[TBL] [Abstract][Full Text] [Related]
12. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.
Palladini G; Milani P; Foli A; Vidus Rosin M; Basset M; Lavatelli F; Nuvolone M; Obici L; Perlini S; Merlini G
Leukemia; 2014 Dec; 28(12):2311-6. PubMed ID: 25059496
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
14. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
15. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Hegenbart U; Bochtler T; Benner A; Becker N; Kimmich C; Kristen AV; Beimler J; Hund E; Zorn M; Freiberger A; Gawlik M; Goldschmidt H; Hose D; Jauch A; Ho AD; Schönland SO
Haematologica; 2017 Aug; 102(8):1424-1431. PubMed ID: 28522573
[TBL] [Abstract][Full Text] [Related]
17. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
18. [Autologous peripheral blood hematopoietic stem cell transplantation for patients with primary light chain amyloidosis: experience of 31 cases in a single center].
Li J; Feng J; Cao XX; Zhang CL; Shen KN; Huang XF; Zhang CL; Duan MH; Zhang W; Zhu TN; Cai HC; Zhang L; Cai H; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):201-4. PubMed ID: 27033756
[TBL] [Abstract][Full Text] [Related]
19. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study.
Katoh N; Ueno A; Yoshida T; Tazawa KI; Shimojima Y; Gono T; Sekijima Y; Matsuda M; Ikeda SI
Int J Hematol; 2017 Mar; 105(3):341-348. PubMed ID: 27832515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
